サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1678533

てんかん治療薬の世界市場：市場規模・シェア・動向分析 (治療法別・流通チャネル別・地域別)、セグメント別予測 (2025年～2030年)

Epilepsy Drugs Market Size, Share & Trends Analysis Report By Treatment (First Generation Anti-epileptics, Second Generation Anti-epileptics), By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030

出版日
ページ情報
英文 90 Pages
納期
2～10営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=143.57円
てんかん治療薬の世界市場：市場規模・シェア・動向分析 (治療法別・流通チャネル別・地域別)、セグメント別予測 (2025年～2030年)
出版日: 2025年02月06日
発行: Grand View Research
ページ情報: 英文 90 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

てんかん治療薬市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、世界のてんかん治療薬の市場規模は、2025年から2030年にかけてCAGR 5.7%で拡大し、2030年には154億7,000万米ドルに達すると推定されています。

てんかん発作の治療に有効な新薬の開発に対する政府資金の増加は、てんかん治療薬市場成長のインパクトの大きい促進要因です。米国てんかん協会（AES）は、米国神経学会（American Academy of Neurology）、てんかん財団（Epilepsy Foundation）、グラス財団（Grass Foundation）などのその他の団体と連携して、研究開発活動に資金を提供し、さまざまなプログラムを通じて医師に治療ラインの認識トレーニングを提供しています。

さらに、Epilepsy Foundation、American Epilepsy Society、Epilepsy Association of Central Florida、CURE Epilepsy、Anita Kaufmann Foundationなどの団体が実施する様々な啓発プログラムは、診断率と治療率をさらに加速させています。このことは、予測期間中の市場成長を促進すると予想されます。

てんかん治療薬市場：分析概要

  • 第二世代の抗てんかん薬は、第二の急成長セグメントとなる見込みです。このセグメントには、Lamotrigine（Lamictal）、Levetiracetam（Keppra）、Brivaracetam（Briviact）、Perampanel（Fycompa）などが含まれます。
  • 第三世代抗てんかん薬セグメントは、2024年に約39.7%の最大の売上シェアを占めました。同分野の成長の主な要因としては、作用機序が改善され副作用の少ない有効性の高い薬剤の上市や、新たなパイプライン薬剤の上市待ちなどが挙げられます。
  • 2024年の売上高シェアは、北米が約38.7%で最大となりました。同地域ではてんかんの有病率が高く、罹患者数が多いことが、てんかん治療薬市場の主な牽引要因となっています。
  • アジア太平洋地域のてんかん治療薬市場は、予測期間中に顕著なCAGRを記録すると予想されます。これは、同地域の人口が多く多様であること、てんかんの有病率が急上昇していること、医療インフラが改善されていることなどが要因です。

目次

第1章 分析方法・範囲

第2章 エグゼクティブサマリー

第3章 てんかん治療薬市場：変動要因・傾向・範囲

  • 市場連関の見通し
  • 市場力学
    • 市場促進要因の分析
    • 市場抑制要因の分析
  • ビジネス環境分析
    • 業界分析：ポーターのファイブフォース分析
    • PESTEL分析

第4章 てんかん治療薬市場：治療法別のビジネス分析

  • 市場シェア：治療法別 (2024年・2030年)
  • 治療法別ダッシュボード
  • 市場規模の予測と動向分析：治療法別 (2018～2030年)
  • 第一世代抗てんかん薬
  • 第二世代抗てんかん薬
  • 第三世代抗てんかん薬

第5章 てんかん治療薬市場：流通チャネル別のビジネス分析

  • 市場シェア：流通チャネル別 (2024年・2030年)
  • 流通チャネル別ダッシュボード
  • 市場規模の予測と動向分析：流通チャネル別 (2018～2030年)
  • 病院薬局
  • 小売薬局
  • その他

第6章 てんかん治療薬市場：地域別の推定・動向分析

  • 市場シェア：地域別 (2024年・2030年)
  • 市場ダッシュボード：地域別
  • 市場規模の予測と動向分析 (2018～2030年)
  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • 英国
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • デンマーク
    • ノルウェー
    • スウェーデン
  • アジア太平洋
    • 日本
    • 中国
    • インド
    • 韓国
    • オーストラリア
    • タイ
  • ラテンアメリカ
    • ブラジル
    • アルゼンチン
  • 中東・アフリカ
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • クウェート

第7章 競合情勢

  • 参入企業概要
  • 企業の市場ポジション分析
  • 企業分類
  • 戦略マッピング
  • 企業プロファイル/上場企業
    • UCB SA
    • Sanofi
    • Pfizer, Inc.
    • Otsuka America Pharmaceutical, Inc.
    • Eisai Co., Ltd.
    • Abbott Laboratories, Inc.
    • Novartis AG
    • GlaxoSmithKline plc
    • Sunovion Pharmaceuticals, Inc.
    • Jazz Pharmaceuticals plc
    • Neurelis, Inc.
図表

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 Global Epilepsy Drugs Market, By Region, 2018 - 2030 (USD Million)
  • Table 4 Global Epilepsy Drugs Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 5 Global Epilepsy Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 6 North America Epilepsy Drugs Market, By Country, 2018 - 2030 (USD Million)
  • Table 7 North America Epilepsy Drugs Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 8 North America Epilepsy Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 9 U.S. Epilepsy Drugs Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 10 U.S. Epilepsy Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 11 Canada Epilepsy Drugs Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 12 Canada Epilepsy Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 13 Mexico Epilepsy Drugs Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 14 Mexico Epilepsy Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 15 Europe Epilepsy Drugs Market, By Country, 2018 - 2030 (USD Million)
  • Table 16 Europe Epilepsy Drugs Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 17 Europe Epilepsy Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 18 U.K. Epilepsy Drugs Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 19 U.K. Epilepsy Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 20 Germany Epilepsy Drugs Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 21 Germany Epilepsy Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 22 France Epilepsy Drugs Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 23 France Epilepsy Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 24 Italy Epilepsy Drugs Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 25 Italy Epilepsy Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 26 Spain Epilepsy Drugs Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 27 Spain Epilepsy Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 28 Denmark Epilepsy Drugs Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 29 Denmark Epilepsy Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 30 Norway Epilepsy Drugs Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 31 Norway Epilepsy Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 32 Sweden Epilepsy Drugs Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 33 Sweden Epilepsy Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 34 Asia Pacific Epilepsy Drugs Market, By Country, 2018 - 2030 (USD Million)
  • Table 35 Asia Pacific Epilepsy Drugs Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 36 Asia Pacific Epilepsy Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 37 Japan Epilepsy Drugs Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 38 Japan Epilepsy Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 39 China Epilepsy Drugs Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 40 China Epilepsy Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 41 India Epilepsy Drugs Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 42 India Epilepsy Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 43 South Korea Epilepsy Drugs Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 44 South Korea Epilepsy Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 45 Australia Epilepsy Drugs Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 46 Australia Epilepsy Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 47 Thailand Epilepsy Drugs Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 48 Thailand Epilepsy Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 49 Latin America Epilepsy Drugs Market, By Country, 2018 - 2030 (USD Million)
  • Table 50 Latin America Epilepsy Drugs Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 51 Latin America Epilepsy Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 52 Brazil Epilepsy Drugs Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 53 Brazil Epilepsy Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 54 Argentina Epilepsy Drugs Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 55 Argentina Epilepsy Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 56 Middle East & Africa Epilepsy Drugs Market, By Country, 2018 - 2030 (USD Million)
  • Table 57 Middle East & Africa Epilepsy Drugs Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 58 Middle East & Africa Epilepsy Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 59 South Africa Epilepsy Drugs Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 60 South Africa Epilepsy Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 61 Saudi Arabia Epilepsy Drugs Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 62 Saudi Arabia Epilepsy Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 63 UAE Epilepsy Drugs Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 64 UAE Epilepsy Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 65 Kuwait Epilepsy Drugs Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 66 Kuwait Epilepsy Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Epilepsy Drugs Market Segmentation
  • Fig. 2 Market Research Process
  • Fig. 3 Data Triangulation Techniques
  • Fig. 4 Primary Research Pattern
  • Fig. 5 Market Research Approaches
  • Fig. 6 Value-Chain-Based Sizing & Forecasting
  • Fig. 7 Market Formulation & Validation
  • Fig. 8 Market Snapshot

Fig. 9 Treatment and Distribution Channel Outlook (USD Million)

  • Fig. 10 Competitive Landscape
  • Fig. 11 Epilepsy Drugs Market Dynamics
  • Fig. 12 Epilepsy Drugs Market: Porter's Five Forces Analysis
  • Fig. 13 Epilepsy Drugs Market: PESTLE Analysis
  • Fig. 14 Epilepsy Drugs Market: Treatment Segment Dashboard
  • Fig. 15 Epilepsy Drugs Market: Treatment Market Share Analysis, 2024 & 2030
  • Fig. 16 First Generation Anti-epileptics Market, 2018 - 2030 (USD Million)
  • Fig. 17 Second Generation Anti-epileptics Market, 2018 - 2030 (USD Million)
  • Fig. 18 Third Generation Anti-epileptics Market, 2018 - 2030 (USD Million)
  • Fig. 19 Epilepsy Drugs Market: Distribution Channel Segment Dashboard
  • Fig. 20 Epilepsy Drugs Market: Distribution Channel Market Share Analysis, 2024 & 2030
  • Fig. 21 Hospital Pharmacies Market, 2018 - 2030 (USD Million)
  • Fig. 22 Retail Pharmacies Market, 2018 - 2030 (USD Million)
  • Fig. 23 Others Market, 2018 - 2030 (USD Million)
  • Fig. 24 Epilepsy Drugs Market Revenue, By Region
  • Fig. 25 Regional Marketplace: Key Takeaways
  • Fig. 26 Regional Marketplace: Key Takeaways
  • Fig. 27 North America Epilepsy Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 28 U.S. Country Dynamics
  • Fig. 29 U.S. Epilepsy Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 30 Canada Country Dynamics
  • Fig. 31 Canada Epilepsy Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 32 Mexico Country Dynamics
  • Fig. 33 Mexico Epilepsy Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 34 Europe Epilepsy Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 35 U.K. Country Dynamics
  • Fig. 36 U.K. Epilepsy Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 37 Germany Country Dynamics
  • Fig. 38 Germany Epilepsy Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 39 France Country Dynamics
  • Fig. 40 France Epilepsy Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 41 Italy Country Dynamics
  • Fig. 42 Italy Epilepsy Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 43 Spain Country Dynamics
  • Fig. 44 Spain Epilepsy Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 45 Denmark Country Dynamics
  • Fig. 46 Denmark Epilepsy Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 47 Norway Country Dynamics
  • Fig. 48 Norway Epilepsy Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 49 Sweden Country Dynamics
  • Fig. 50 Sweden Epilepsy Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 51 Asia Pacific Epilepsy Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 52 Japan Country Dynamics
  • Fig. 53 Japan Epilepsy Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 54 China Country Dynamics
  • Fig. 55 China Epilepsy Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 56 India Country Dynamics
  • Fig. 57 India Epilepsy Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 58 South Korea Country Dynamics
  • Fig. 59 South Korea Epilepsy Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 60 Australia Country Dynamics
  • Fig. 61 Australia Epilepsy Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 62 Thailand Country Dynamics
  • Fig. 63 Thailand Epilepsy Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 64 Latin America Epilepsy Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 65 Brazil Country Dynamics
  • Fig. 66 Brazil Epilepsy Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 67 Argentina Country Dynamics
  • Fig. 68 Argentina Epilepsy Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 69 Middle East & Africa Epilepsy Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 70 South Africa Country Dynamics
  • Fig. 71 South Africa Epilepsy Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 72 Saudi Arabia Country Dynamics
  • Fig. 73 Saudi Arabia Epilepsy Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 74 UAE Country Dynamics
  • Fig. 75 UAE Epilepsy Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 76 Kuwait Key Country Dynamicss
  • Fig. 77 Kuwait Epilepsy Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 78 Company Categorization
  • Fig. 79 Company Market Position Analysis
  • Fig. 80 Strategic Framework
目次
Product Code: 978-1-68038-958-6

Epilepsy Drugs Market Growth & Trends:

The global epilepsy drugs market size is estimated to reach USD 15.47 billion by 2030, expanding at a CAGR of 5.7% from 2025 to 2030, according to a new report by Grand View Research, Inc. The rising government funding for the development of new and effective drugs for the treatment of seizures is a high impact rendering driver for the epilepsy drugs market growth. The American Epilepsy Society (AES) in alliance with other organizations, such as American Academy of Neurology, the Epilepsy Foundation, and the Grass Foundation, provide funding for R&D activities and offer treatment line awareness trainingto the physicians through different programs.

Furthermore, various awareness programs conducted by organizations, such as the Epilepsy Foundation, the American Epilepsy Society, Epilepsy Association of Central Florida, CURE Epilepsy, and the Anita Kaufmann Foundation, further accelerate the diagnosis and treatment rates. This is expected to propel the market growth over the forecast period.

Epilepsy Drugs Market Report Highlights:

  • Second generation anti-epileptics are expected to be the second-fastest-growing segment. This segment includes Lamotrigine (Lamictal), Levetiracetam (Keppra), Brivaracetam (Briviact), and Perampanel (Fycompa).
  • The third generation anti-epileptics segment accounted for the largest revenue share of around 39.7% in 2024. The major factors responsible for the growth of this segment include the launch of high efficacy drugs with improved mechanism of action and fewer side effects, and the awaited launch of new pipeline drugs.
  • North America dominated the market with the largest revenue share of around 38.7% in 2024. The high prevalence of epilepsy in the region, with a significant number of people affected by the condition, is a major driving factor for the epilepsy drugs market.
  • Asia Pacific epilepsy drugs market is expected to register at a notable CAGR over the forecast period, attributed to the large and diverse population of the region, surging prevalence of epilepsy, and improving healthcare infrastructure.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Treatment
    • 1.2.2. Distribution Channel
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Epilepsy Drugs Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTLE Analysis

Chapter 4. Epilepsy Drugs Market: Treatment Business Analysis

  • 4.1. Treatment Market Share, 2024 & 2030
  • 4.2. Treatment Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, By Treatment, 2018 to 2030 (USD Million)
  • 4.4. First Generation Anti-epileptics
    • 4.4.1. First Generation Anti-epileptics Market, 2018 - 2030 (USD Million)
  • 4.5. Second Generation Anti-epileptics
    • 4.5.1. Second Generation Anti-epileptics Market, 2018 - 2030 (USD Million)
  • 4.6. Third Generation Anti-epileptics
    • 4.6.1. Third Generation Anti-epileptics Market, 2018 - 2030 (USD Million)

Chapter 5. Epilepsy Drugs Market: Distribution Channel Business Analysis

  • 5.1. Distribution Channel Market Share, 2024 & 2030
  • 5.2. Distribution Channel Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, By Distribution Channel, 2018 to 2030 (USD Million)
  • 5.4. Hospital Pharmacies
    • 5.4.1. Hospital Pharmacies Market, 2018 - 2030 (USD Million)
  • 5.5. Retail Pharmacies
    • 5.5.1. Retail Pharmacies Market, 2018 - 2030 (USD Million)
  • 5.6. Others
    • 5.6.1. Others Market, 2018 - 2030 (USD Million)

Chapter 6. Epilepsy Drugs Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Market Share Analysis, 2024 & 2030
  • 6.2. Regional Market Dashboard
  • 6.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 6.4. North America
    • 6.4.1. North America Epilepsy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.2. U.S.
      • 6.4.2.1. Key Country Dynamics
      • 6.4.2.2. Regulatory Framework
      • 6.4.2.3. Competitive Insights
      • 6.4.2.4. U.S. Epilepsy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.3. Canada
      • 6.4.3.1. Key Country Dynamics
      • 6.4.3.2. Regulatory Framework
      • 6.4.3.3. Competitive Insights
      • 6.4.3.4. Canada Epilepsy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.4. Mexico
      • 6.4.4.1. Key Country Dynamics
      • 6.4.4.2. Regulatory Framework
      • 6.4.4.3. Competitive Insights
      • 6.4.4.4. Mexico Epilepsy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5. Europe
    • 6.5.1. Europe Epilepsy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.2. U.K.
      • 6.5.2.1. Key Country Dynamics
      • 6.5.2.2. Regulatory Framework
      • 6.5.2.3. Competitive Insights
      • 6.5.2.4. U.K. Epilepsy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.3. Germany
      • 6.5.3.1. Key Country Dynamics
      • 6.5.3.2. Regulatory Framework
      • 6.5.3.3. Competitive Insights
      • 6.5.3.4. Germany Epilepsy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.4. France
      • 6.5.4.1. Key Country Dynamics
      • 6.5.4.2. Regulatory Framework
      • 6.5.4.3. Competitive Insights
      • 6.5.4.4. France Epilepsy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.5. Italy
      • 6.5.5.1. Key Country Dynamics
      • 6.5.5.2. Regulatory Framework
      • 6.5.5.3. Competitive Insights
      • 6.5.5.4. Italy Epilepsy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.6. Spain
      • 6.5.6.1. Key Country Dynamics
      • 6.5.6.2. Regulatory Framework
      • 6.5.6.3. Competitive Insights
      • 6.5.6.4. Spain Epilepsy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.7. Denmark
      • 6.5.7.1. Key Country Dynamics
      • 6.5.7.2. Regulatory Framework
      • 6.5.7.3. Competitive Insights
      • 6.5.7.4. Denmark Epilepsy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.8. Norway
      • 6.5.8.1. Key Country Dynamics
      • 6.5.8.2. Regulatory Framework
      • 6.5.8.3. Competitive Insights
      • 6.5.8.4. Norway Epilepsy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.9. Sweden
      • 6.5.9.1. Key Country Dynamics
      • 6.5.9.2. Regulatory Framework
      • 6.5.9.3. Competitive Insights
      • 6.5.9.4. Sweden Epilepsy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6. Asia Pacific
    • 6.6.1. Asia Pacific Epilepsy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.2. Japan
      • 6.6.2.1. Key Country Dynamics
      • 6.6.2.2. Regulatory Framework
      • 6.6.2.3. Competitive Insights
      • 6.6.2.4. Japan Epilepsy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.3. China
      • 6.6.3.1. Key Country Dynamics
      • 6.6.3.2. Regulatory Framework
      • 6.6.3.3. Competitive Insights
      • 6.6.3.4. China Epilepsy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.4. India
      • 6.6.4.1. Key Country Dynamics
      • 6.6.4.2. Regulatory Framework
      • 6.6.4.3. Competitive Insights
      • 6.6.4.4. India Epilepsy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.5. South Korea
      • 6.6.5.1. Key Country Dynamics
      • 6.6.5.2. Regulatory Framework
      • 6.6.5.3. Competitive Insights
      • 6.6.5.4. South Korea Epilepsy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.6. Australia
      • 6.6.6.1. Key Country Dynamics
      • 6.6.6.2. Regulatory Framework
      • 6.6.6.3. Competitive Insights
      • 6.6.6.4. Australia Epilepsy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.7. Thailand
      • 6.6.7.1. Key Country Dynamics
      • 6.6.7.2. Regulatory Framework
      • 6.6.7.3. Competitive Insights
      • 6.6.7.4. Thailand Epilepsy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.7. Latin America
    • 6.7.1. Latin America Epilepsy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.7.2. Brazil
      • 6.7.2.1. Key Country Dynamics
      • 6.7.2.2. Regulatory Framework
      • 6.7.2.3. Competitive Insights
      • 6.7.2.4. Brazil Epilepsy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.7.3. Argentina
      • 6.7.3.1. Key Country Dynamics
      • 6.7.3.2. Regulatory Framework
      • 6.7.3.3. Competitive Insights
      • 6.7.3.4. Argentina Epilepsy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.8. Middle East and Africa
    • 6.8.1. Middle East and Africa Epilepsy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.8.2. South Africa
      • 6.8.2.1. Key Country Dynamics
      • 6.8.2.2. Regulatory Framework
      • 6.8.2.3. Competitive Insights
      • 6.8.2.4. South Africa Epilepsy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.8.3. Saudi Arabia
      • 6.8.3.1. Key Country Dynamics
      • 6.8.3.2. Regulatory Framework
      • 6.8.3.3. Competitive Insights
      • 6.8.3.4. Saudi Arabia Epilepsy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.8.4. UAE
      • 6.8.4.1. Key Country Dynamics
      • 6.8.4.2. Regulatory Framework
      • 6.8.4.3. Competitive Insights
      • 6.8.4.4. UAE Epilepsy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.8.5. Kuwait
      • 6.8.5.1. Key Country Dynamics
      • 6.8.5.2. Regulatory Framework
      • 6.8.5.3. Competitive Insights
      • 6.8.5.4. Kuwait Epilepsy Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Participant Overview
  • 7.2. Company Market Position Analysis
  • 7.3. Company Categorization
  • 7.4. Strategy Mapping
  • 7.5. Company Profiles/Listing
    • 7.5.1. UCB S.A.
      • 7.5.1.1. Participant's Overview
      • 7.5.1.2. Financial Performance
      • 7.5.1.3. Product Benchmarking
      • 7.5.1.4. Strategic Initiatives
    • 7.5.2. Sanofi
      • 7.5.2.1. Participant's Overview
      • 7.5.2.2. Financial Performance
      • 7.5.2.3. Product Benchmarking
      • 7.5.2.4. Strategic Initiatives
    • 7.5.3. Pfizer, Inc.
      • 7.5.3.1. Participant's Overview
      • 7.5.3.2. Financial Performance
      • 7.5.3.3. Product Benchmarking
      • 7.5.3.4. Strategic Initiatives
    • 7.5.4. Otsuka America Pharmaceutical, Inc.
      • 7.5.4.1. Participant's overview
      • 7.5.4.2. Financial Performance
      • 7.5.4.3. Product Benchmarking
      • 7.5.4.4. Strategic Initiatives
    • 7.5.5. Eisai Co., Ltd.
      • 7.5.5.1. Participant's Overview
      • 7.5.5.2. Financial Performance
      • 7.5.5.3. Product Benchmarking
      • 7.5.5.4. Strategic Initiatives
    • 7.5.6. Abbott Laboratories, Inc.
      • 7.5.6.1. Participant's Overview
      • 7.5.6.2. Financial Performance
      • 7.5.6.3. Product Benchmarking
      • 7.5.6.4. Strategic Initiatives
    • 7.5.7. Novartis AG
      • 7.5.7.1. Participant's Overview
      • 7.5.7.2. Financial Performance
      • 7.5.7.3. Product Benchmarking
      • 7.5.7.4. Strategic Initiatives
    • 7.5.8. GlaxoSmithKline plc
      • 7.5.8.1. Participant's Overview
      • 7.5.8.2. Financial Performance
      • 7.5.8.3. Product Benchmarking
      • 7.5.8.4. Strategic Initiatives
    • 7.5.9. Sunovion Pharmaceuticals, Inc.
      • 7.5.9.1. Participant's Overview
      • 7.5.9.2. Financial Performance
      • 7.5.9.3. Product Benchmarking
      • 7.5.9.4. Strategic Initiatives
    • 7.5.10. Jazz Pharmaceuticals plc
      • 7.5.10.1. Participant's Overview
      • 7.5.10.2. Financial Performance
      • 7.5.10.3. Product Benchmarking
      • 7.5.10.4. Strategic Initiatives
    • 7.5.11. Neurelis, Inc.
      • 7.5.11.1. Participant's Overview
      • 7.5.11.2. Financial Performance
      • 7.5.11.3. Product Benchmarking
      • 7.5.11.4. Strategic Initiatives